GoodRx files 8-K saying Q1, Q2 2026 financials can no longer be relied upon after understating pharma direct revenue by $29.773M

GoodRx Holdings, Inc. filed a Form 8-K with the SEC on 2026-11-02 disclosing Item 4.02: non-reliance on previously issued financial statements. The company said Q1 and Q2 2026 financials can no longer be relied upon after understating pharma direct revenue by $29.773M, and expects material weaknesses in internal control for those periods.

Detected & updated continuously · Source: Nebula